Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?
Scienture (SCNX) shares surged 40% to $0.99 pre-market Nov. 4 after its hypertension drug Arbli™ was added to major insurance formularies, expanding coverage to over 100 million people. The company reported just $0.13 million in revenue and a $20 million net loss over the past year. SCNX trades near $0.71, down from a 52-week high of $8.81. Analysts remain cautious, citing high cash burn and uncertain Arbli sales.
